Replay Conf call - Janssen deal & Replay Webcast - ITP Ph2 & AML Ph1/2 data

2010

arGEN-X appoints Dr Debbie Allen as Senior Director Business Development

November 05, 2010

Rotterdam, The Netherlands – arGEN-X BV, a biopharmaceutical company focused on the discovery and development of human antibodies using its proprietary SIMPLE Antibody™ platform, today announced the appointment of Dr Debbie Allen as Senior Director Business Development. Dr Allen brings to arGEN-X more than 12 years of corporate and business development experience with small and large biotech companies.

arGEN-X awarded €1.5 million iwt grant to accelerate pre-clinical antibody development

September 27, 2010

  • ARGX-109 and Two Further Human Antibody Development Candidates Generated From Unique SIMPLE Antibody™ platform

Rotterdam, The Netherlands – arGEN-X BV, a biopharmaceutical company focused on the discovery and development of therapeutic human antibodies (mAbs), today announced that it has received a €1.5 million grant from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT). This grant will be used to accelerate pre-clinical development of the lead program, ARGX-109 and two further therapeutic mAb programs. All three mAb candidates originated from arGEN-X’s proprietary SIMPLE Antibody™ platform and are being developed by the Company to target the inflammation/oncology space.

arGEN-X granted broad patent covering its unique simple antibody™ platform

July 08, 2010

  • Novel Platform Set to Transform Human Therapeutic Antibody Discovery & Development

Rotterdam, the Netherlands – arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies using its proprietary SIMPLE Antibody™ platform, announces that it has been granted the first patent covering the platform. The patent GB2461546B, has been granted by the UK Patent and Trademark Office (UKPTO).

arGEN-X concludes EUR 12.5 million Series A financing round

April 20, 2010

Rotterdam, The Netherlands – arGEN-X BV, a biopharmaceutical company focused on the discovery and development of human antibodies using its proprietary SIMPLE Antibody™ platform, today announced the successful second closing of its Series A equity financing round. The Company raised an additional EUR 3.0 million (~USD 4.5 million) from two leading life science investors, Crédit Agricole Private Equity and VIB (the prestigious Flemish research institute).

arGEN-X simple antibody™ platform set to transform therapeutic antibody discovery & development

March 01, 2010

  • SIMPLE Antibody™ Platform delivers unprecedented choice of ultra-potent functional antibody leads against challenging soluble and cell surface targets.
  • ARGX-109, a fully human mAb targeting autoimmune, inflammation and oncology indications, enters preclinical development in less than 12 months from start of discovery.

Rotterdam, the Netherlands – arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies using its proprietary SIMPLE Antibody™ platform, announces that it will provide an update on the development of this unique platform and its own antibody pipeline during the BIO-Europe Spring event in Barcelona (March 8-10, 2010).